文献速递复苏、休克与脓毒症消化、代谢与肾脏急症

新型29信使RNA全血宿主反应检测可准确识别急诊疑似感染患者的细菌与病毒感染:一项前瞻性观察研究

A Novel 29-Messenger RNA Host-Response Assay From Whole Blood Accurately Identifies Bacterial and Viral Infections in Patients Presenting to the Emergency Department With Suspected Infections: A Prospective Observational Study.
PubMed 文献 · Crit Care Med · 2021-01-01
一句话结论在急诊疑似感染成人中,IMX-BVN-2细菌评分鉴别细菌感染的AUC为0.90,病毒评分鉴别病毒感染的AUC为0.83,显示宿主反应检测辅助判断感染病因的潜力。

该前瞻性观察研究在德国柏林Charité-Universitätsmedizin Berlin本杰明·富兰克林院区急诊科纳入312例疑似急性感染或脓毒症、且至少有一项生命体征改变的成人患者,无干预。用NanoString nCounter SPRINT平台定量全血RNA,经IMX-BVN-2神经网络分类器计算细菌与病毒感染预测概率。IMX-BVN-2细菌评分鉴别裁定细菌感染与排除细菌感染的AUC为0.90(95%CI 0.85-0.95),降钙素原为0.89(95%CI 0.84-0.94),且降钙素原被用于裁定过程;病毒评分鉴别裁定病毒感染与排除病毒感染的AUC为0.83(95%CI 0.77-0.89)。作者认为该检测对病毒和细菌感染均显示准确性,提示宿主反应检测作为确定感染病因的新型实用方法具有潜力,可能改善患者结局并兼顾抗菌药物管理。

要点

  • 312例急诊疑似急性感染或脓毒症、至少一项生命体征改变的成人中,IMX-BVN-2细菌评分鉴别裁定细菌感染的AUC为0.90(95%CI 0.85-0.95)。
  • 降钙素原鉴别裁定细菌感染的AUC为0.89(95%CI 0.84-0.94),但降钙素原被用于裁定过程。
  • IMX-BVN-2病毒评分鉴别裁定病毒感染的AUC为0.83(95%CI 0.77-0.89)。
  • IMX-BVN-2为全血29信使RNA宿主反应神经网络分类器,在独立开发集训练后于本队列前瞻性验证。
  • 作者认为宿主反应检测是确定感染病因的新型实用方法,可能改善结局并兼顾抗菌药物管理。

适用人群与场景

  • 德国柏林Charité-Universitätsmedizin Berlin本杰明·富兰克林院区急诊科就诊的成人患者。
  • 疑似急性感染或脓毒症,且至少有一项生命体征改变。

研究设计与关键结果

  • 研究类型为前瞻性观察研究,纳入312例急诊疑似急性感染或脓毒症成人,无干预。
  • 全血RNA经NanoString nCounter SPRINT定量,用IMX-BVN-2神经网络分类器(在独立开发集训练)计算细菌与病毒感染预测概率。
  • IMX-BVN-2细菌评分鉴别裁定细菌感染与排除细菌感染的AUC为0.90(95%CI 0.85-0.95)。
  • 降钙素原鉴别裁定细菌感染与排除细菌感染的AUC为0.89(95%CI 0.84-0.94),降钙素原被用于裁定过程。
  • IMX-BVN-2病毒评分鉴别裁定病毒感染与排除病毒感染的AUC为0.83(95%CI 0.77-0.89)。

证据类型、等级与局限

  • 证据类型:前瞻性观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为IMX-BVN-2对病毒感染和细菌感染均显示准确性,宿主反应检测作为确定感染病因的新型实用方法具有潜力,可能改善患者结局并兼顾抗菌药物管理。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: The rapid diagnosis of acute infections and sepsis remains a serious challenge. As a result of limitations in current diagnostics, guidelines recommend early antimicrobials for suspected sepsis patients to improve outcomes at a cost to antimicrobial stewardship. We aimed to develop and prospectively validate a new, 29-messenger RNA blood-based host-response classifier Inflammatix Bacterial Viral Non-Infected version 2 (IMX-BVN-2) to determine the likelihood of bacterial and viral infections.

DESIGN: Prospective observational study.

SETTING: Emergency Department, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Germany.

PATIENTS: Three hundred twelve adult patients presenting to the emergency department with suspected acute infections or sepsis with at least one vital sign change.

INTERVENTIONS: None (observational study only).

MEASUREMENTS AND MAIN RESULTS: Gene expression levels from extracted whole blood RNA was quantified on a NanoString nCounter SPRINT (NanoString Technologies, Seattle, WA). Two predicted probability scores for the presence of bacterial and viral infection were calculated using the IMX-BVN-2 neural network classifier, which was trained on an independent development set. The IMX-BVN-2 bacterial score showed an area under the receiver operating curve for adjudicated bacterial versus ruled out bacterial infection of 0.90 (95% CI, 0.85-0.95) compared with 0.89 (95% CI, 0.84-0.94) for procalcitonin with procalcitonin being used in the adjudication. The IMX-BVN-2 viral score area under the receiver operating curve for adjudicated versus ruled out viral infection was 0.83 (95% CI, 0.77-0.89).

CONCLUSIONS: IMX-BVN-2 demonstrated accuracy for detecting both viral infections and bacterial infections. This shows the potential of host-response tests as a novel and practical approach for determining the causes of infections, which could improve patient outcomes while upholding antimicrobial stewardship.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Bauer W, Kappert K, Galtung N, et al. A Novel 29-Messenger RNA Host-Response Assay From Whole Blood Accurately Identifies Bacterial and Viral Infections in Patients Presenting to the Emergency Department With Suspected Infections: A Prospective Observational Study. Crit Care Med. 2021. PMID: 34166284. doi:10.1097/CCM.0000000000005119

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。